These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 34348634)
1. Pharmacological Basis of Breast Cancer Resistance to Therapies - An Overview. Crucitta S; Cucchiara F; Sciandra F; Cerbioni A; Diodati L; Rafaniello C; Capuano A; Fontana A; Fogli S; Danesi R; Re MD Anticancer Agents Med Chem; 2022; 22(4):760-774. PubMed ID: 34348634 [TBL] [Abstract][Full Text] [Related]
2. Overview of resistance to systemic therapy in patients with breast cancer. Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229 [TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapeutic options for patients with refractory breast cancer. Fedele P; Ciccarese M; Surico G; Cinieri S Expert Opin Pharmacother; 2019 May; 20(7):851-861. PubMed ID: 30730767 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for Breast Cancer Treatment: Current Evidence and Therapeutic Options. Singh K; Yadav D; Jain M; Singh PK; Jin JO Endocr Metab Immune Disord Drug Targets; 2022; 22(2):212-224. PubMed ID: 33902424 [TBL] [Abstract][Full Text] [Related]
6. The therapeutic potential of immunotherapy in the treatment of breast cancer: Rational strategies and recent progress. Javid H; Attarian F; Saadatmand T; Rezagholinejad N; Mehri A; Amiri H; Karimi-Shahri M J Cell Biochem; 2023 Apr; 124(4):477-494. PubMed ID: 36966454 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974 [TBL] [Abstract][Full Text] [Related]
9. Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. Wang Y; Minden A Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232349 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic significance of hormone receptor positivity in patients with HER-2 positive breast cancer. Kolarova I; Vanasek J; Odrazka K; Melichar B; Ryska A; Petera J; Vosmik M; Dolezel M Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2019 Dec; 163(4):285-292. PubMed ID: 31831888 [TBL] [Abstract][Full Text] [Related]
11. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer. Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014 [TBL] [Abstract][Full Text] [Related]
12. Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers. Miranda F; Prazeres H; Mendes F; Martins D; Schmitt F Mol Biol Rep; 2022 Jan; 49(1):717-733. PubMed ID: 34739691 [TBL] [Abstract][Full Text] [Related]
13. Molecular classification of infiltrating breast cancer: toward personalized therapy. Trop I; LeBlanc SM; David J; Lalonde L; Tran-Thanh D; Labelle M; El Khoury MM Radiographics; 2014; 34(5):1178-95. PubMed ID: 25208275 [TBL] [Abstract][Full Text] [Related]
14. The next generation personalized models to screen hidden layers of breast cancer tumorigenicity. Afzali F; Akbari P; Naderi-Manesh H; Gardaneh M Breast Cancer Res Treat; 2019 Jun; 175(2):277-286. PubMed ID: 30810866 [TBL] [Abstract][Full Text] [Related]
15. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. Gu G; Dustin D; Fuqua SA Curr Opin Pharmacol; 2016 Dec; 31():97-103. PubMed ID: 27883943 [TBL] [Abstract][Full Text] [Related]
16. Global View of Candidate Therapeutic Target Genes in Hormone-Responsive Breast Cancer. Salvati A; Gigantino V; Nassa G; Mirici Cappa V; Ventola GM; Cracas DGC; Mastrocinque R; Rizzo F; Tarallo R; Weisz A; Giurato G Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517194 [TBL] [Abstract][Full Text] [Related]
17. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. Yang R; Li Y; Wang H; Qin T; Yin X; Ma X Mol Biomed; 2022 Mar; 3(1):8. PubMed ID: 35243562 [TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast cancer: current state of the art. Rastelli F; Biancanelli S; Falzetta A; Martignetti A; Casi C; Bascioni R; Giustini L; Crispino S Tumori; 2010; 96(6):875-88. PubMed ID: 21388048 [TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer. De La Cruz LM; Czerniecki BJ Ann Surg Oncol; 2018 Oct; 25(10):2852-2857. PubMed ID: 30014455 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]